Publications by authors named "Elodie Bourgeois-Cayer"
Pharmacokinetic profile of bitopertin, a selective GlyT inhibitor, in the rat.
Naunyn Schmiedebergs Arch Pharmacol
May 2023
Article Synopsis
- Bitopertin, a drug inhibiting glycine transporter 1, has been studied for schizophrenia treatment, especially regarding its safety and tolerability in clinical settings.
- This study aimed to determine the pharmacokinetic (PK) profile of bitopertin in female Sprague-Dawley rats, using various dosing methods and advanced analytic techniques.
- Results showed that bitopertin is slowly absorbed and eliminated, demonstrating a linear relationship between dose and drug exposure, which may help in designing future pre-clinical experiments for subcutaneous administration.
Dyskinesia remains an unmet need in Parkinson's disease (PD). We have previously demonstrated that glycine transporter 1 (GlyT1) inhibition with ALX-5407 reduces dyskinesia and slightly improves parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Here, we sought to determine the effect of bitopertin, a clinically-tested GlyT1 inhibitor, on parkinsonism and dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.
View Article and Find Full Text PDFL-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective therapy for motor symptoms of Parkinson's disease (PD); however, with repeated administration, as many as 94% of PD patients develop complications such as L-DOPA-induced dyskinesia. We previously demonstrated that EMD-281,014, a highly selective serotonin 2A (5-HT) receptor antagonist, reduces the severity of dyskinesia in the parkinsonian marmoset, without interfering with L-DOPA anti-parkinsonian benefit. Here, we assessed the effects of EMD-281,014 on L-DOPA-induced abnormal involuntary movements (AIMs) in the 6-hydroxydopamine (6-OHDA)-lesioned rat.
View Article and Find Full Text PDF